Targeted Long Acting HIV Therapy intended to clear virus in tissues and cells
Click here to visit the TLC-ART website.
The TLC-ART 1 program, founded by Drs. Ho and Collier, leverages on technical, regulatory, and clinical innovations in the fundamental and biomedical research translation to accelerate discovery into product concepts that will have impacts on infections and cancer or other chronic diseases.
The discovery of the DcNP-enabled drug-combination for current HIV drugs, lopinavir, ritonavir, and tenofovir, assembled as the TLC-ART 101 injectable product also extends plasma and cell drug presence, the TLC-ART 101 is considered long-acting drug product candidate, which is currently a clinical-stage product of the TLC-ART program. Phase 1 clinical testing is funded by NIAID/NIH.
Current focuses include infectious diseases (HIV & HBV treatments) and cancers (breast cancer & pancreatic cancer with GT-DcNP). The projects are supported through public-private partnerships and we thank our sponsors and supporters for their support. Major funding was received from the NIH and Unitaid.
UWMC H-Wing rm H115
1959 NE Pacific St.
Health Sciences Building
Seattle, WA 98195
Phone: (206) 543-8769
Fax: (206) 543-3204
or e-mail email@example.com directly
Principle Investigator: Dr. Rodney JY Ho, PhD, FAAAS, FAAPS